Sex
|
Male sex |
251 |
78 |
Female sex |
70 |
22 |
Smoking status
|
Non-smoker |
61 |
20 |
Smoker or ex-smoker |
252 |
81 |
Performance status
|
ECOG 0 |
59 |
19 |
ECOG I |
235 |
76 |
ECOG >II |
16 |
5 |
Adjuvant therapy
|
Adjuvant chemotherapy |
8 |
3 |
Adjuvant radiotherapy |
38 |
12 |
Tumor stage
|
Stage I |
187 |
58 |
Stage II |
83 |
26 |
Stage III |
51 |
16 |
Tumor size
|
pT1 |
99 |
31 |
pT2 |
192 |
60 |
pT3 |
19 |
6 |
pT4 |
11 |
3 |
Lymph nodes status
|
pN0 |
202 |
63 |
|
pN1-3 |
117 |
37 |
Tumor histology
|
Squamous cell carcinoma |
149 |
46 |
Adenocarcinoma |
125 |
39 |
Large cell carcinoma |
47 |
15 |
Tumor grading
|
G1 |
5 |
2 |
G2 |
111 |
35 |
G3-4 |
199 |
63 |
Apoptosis
|
Negative Bcl-2 expression |
231 |
76 |
Positive Bcl-2 expression |
74 |
24 |
Negative Bcl-xl expression |
196 |
66 |
Positive Bcl-xl expression |
101 |
34 |
EGFR mutation status
|
No EGFR mutation |
22 |
79 |
EGFR mutation |
6 |
21 |
Proliferation (ki-67)
|
Negative ki-67 expression |
77 |
24 |
Positive ki-67 expression |
244 |
76 |
PD-1 expression in tumor Infiltrating lymphocytes (TILs)
|
negative lymphocytic expression |
249 |
78 |
negative lymphocytic expression |
72 |
22 |
PD-L1 expression in NSCLC
|
negative tumor expression |
244 |
76 |
positive tumor expression |
77 |
24 |